cardiovascular | cancer | arthritis

The products listed below are in various stages of research and development.  To better understand their status, a brief description of clinical 
trial stages is available. In addition, don't miss The Pharmaceutical Pipeline, an innovative and enjoyable program for learning about the challenges of drug discovery and development.



A potential extension to Searle's established line of anti-aldosterone agents. Elevated levels of the hormone aldosterone are associated with high blood pressure, congestive heart failure and complications of kidney disease. It is believed that eplerenone may cause fewer side effects than similar, existing drugs.

Tissue Factor Pathway Inhibitor (TFPI)

A genetically engineered protein that blocks biochemical processes in the body that lead to blood clotting, inflammation and cell proliferation. TFPI is currently being tested in humans for the treatment of sepsis, a potentially life-threatening condition resulting from severe infection of the blood.


An orally active anti-platelet agent (GPIIb/IIIa receptor antagonist) designed for acute/short-term use in preventing thrombotic complications (blood-clot formation) following percutaneous coronary angioplasty (a surgical treatment for clearing blocked arteries).

Orbofiban Acetate

An orally active anti-platelet agent (GPIIb/IIIa receptor antagonist) designed for long-term use in treating unstable angina (chest pain) and prevention of second thrombotic events (blood-clot formation).


Searle is a leader in the development of blood-cell growth factors designed to manage infection, bleeding and other side effects associated with chemotherapy. Because chemotherapy can lower a patient's blood count, Searle is designing growth factors to restore white blood cells (which help fight infection) and platelets (which allow the blood to clot in response to injury).


An interleukin-3 (IL-3) receptor agonist designed to stimulate bone marrow to produce and release early-stage, or "precursor," blood cells. The drug is intended to help prepare patients for peripheral blood stem cell transplantation following very high-dose chemotherapy.

Myelopoietin (MPO)

A second-generation stimulator of blood-cell growth that interacts with receptors for both interleukin-3 and granulocyte colony stimulating factor (G-CSF). MPO combines into one molecule the benefits of an early-acting growth factor (daniplestim) with a late-acting neutrophil growth factor. The unique mechanism of action of MPO is expected to result in greater replenishment of neutrophils (mature white blood cells) following chemotherapy, the key to preventing infections in cancer patients.



Celecoxib is a member of a new class of drugs known as specific COX-2 inhibitors. Celecoxib is currently being evaluated in Phase III clinical trials to determine if it is effective in the treatment of arthritis without causing damage to the stomach, intestine or kidney.


Next stop on the guided tour is the products on the market page. Or, choose another section to visit:


©1996, Searle. Send questions or comments to or bug reports to